E. Ohman J or Asset Management AB Has $1.34 Million Stock Position in ResMed Inc. (NYSE:RMD)

E. Ohman J or Asset Management AB decreased its stake in ResMed Inc. (NYSE:RMD) by 11.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,500 shares of the medical equipment provider’s stock after selling 700 shares during the period. E. Ohman J or Asset Management AB’s holdings in ResMed were worth $1,343,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Assenagon Asset Management S.A. grew its stake in shares of ResMed by 46.0% in the third quarter. Assenagon Asset Management S.A. now owns 48,931 shares of the medical equipment provider’s stock worth $11,945,000 after acquiring an additional 15,424 shares during the last quarter. International Assets Investment Management LLC boosted its stake in ResMed by 24,311.9% during the third quarter. International Assets Investment Management LLC now owns 26,609 shares of the medical equipment provider’s stock worth $6,496,000 after buying an additional 26,500 shares in the last quarter. Greenleaf Trust boosted its stake in ResMed by 5.6% during the third quarter. Greenleaf Trust now owns 3,268 shares of the medical equipment provider’s stock worth $798,000 after buying an additional 172 shares in the last quarter. Commerzbank Aktiengesellschaft FI acquired a new stake in ResMed during the third quarter worth $226,000. Finally, Lecap Asset Management Ltd. acquired a new stake in ResMed during the third quarter worth $366,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insider Transactions at ResMed

In related news, insider Kaushik Ghoshal sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total value of $1,262,800.00. Following the completion of the transaction, the insider now directly owns 21,788 shares in the company, valued at approximately $5,502,777.28. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Brett Sandercock sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $212.16, for a total value of $212,160.00. Following the completion of the transaction, the chief financial officer now directly owns 89,056 shares in the company, valued at approximately $18,894,120.96. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kaushik Ghoshal sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total value of $1,262,800.00. Following the transaction, the insider now directly owns 21,788 shares of the company’s stock, valued at approximately $5,502,777.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 123,874 shares of company stock worth $28,151,142. 0.71% of the stock is currently owned by company insiders.

ResMed Stock Performance

Shares of NYSE:RMD opened at $256.07 on Friday. The stock has a market capitalization of $37.58 billion, a P/E ratio of 36.95, a P/E/G ratio of 1.94 and a beta of 0.69. ResMed Inc. has a 1-year low of $132.24 and a 1-year high of $260.49. The company has a current ratio of 2.59, a quick ratio of 1.69 and a debt-to-equity ratio of 0.14. The business has a 50-day moving average price of $240.22 and a two-hundred day moving average price of $217.35.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.17. The company had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.19 billion. ResMed had a return on equity of 25.00% and a net margin of 21.79%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.64 EPS. Equities analysts predict that ResMed Inc. will post 9.08 earnings per share for the current year.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $2.12 annualized dividend and a dividend yield of 0.83%. ResMed’s payout ratio is currently 30.59%.

Analyst Ratings Changes

RMD has been the topic of a number of recent research reports. Robert W. Baird lifted their price target on shares of ResMed from $280.00 to $283.00 and gave the stock an “outperform” rating in a research note on Friday. KeyCorp lifted their price objective on ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a report on Friday. Wolfe Research reissued an “underperform” rating and set a $180.00 price objective on shares of ResMed in a report on Wednesday, September 18th. StockNews.com raised ResMed from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Finally, Needham & Company LLC reissued a “hold” rating on shares of ResMed in a report on Friday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and an average target price of $220.55.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.